Pharmaceutical companies are investing in weight management solutions, with Eli Lilly's oral pill orforglipron showing promising Phase 3 trial results in weight maintenance. Data revealed from ATTAIN-MAINTAIN Phase 3 trial, evaluating orforglipron for weight maintenance over 52 weeks, in individuals who initially received treatment with Novo Nordisk's Wegovy or Zepbound.

Pharmaceutical companies are investing heavily in developing weight management solutions due to the global obesity epidemic, resulting in a rise in clinical trials for anti-obesity medications. Recent advancements in drug development are increasingly focusing on long-term sustainability and safety for individuals struggling with weight maintenance. Eli Lilly and Co (LLY) released topline results from the ATTAIN-MAINTAIN Phase 3 trial of orforglipron. This study evaluated orforglipron for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Novo Nordisk A/S's (NVO) Wegovy (semaglutide) or Zepbound (tirzepatide). Participants from SURMOUNT-5 were re-randomized to receive orforglipron or placebo. For more information, the full story is available on Benzinga.com.